Wedbush Initiates Coverage On Camp4 Therapeutics with Outperform Rating, Announces Price Target of $8
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Wedbush analyst Yun Zhong initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform rating and announces Price Target of $8.
Wedbush analyst Yun Zhong initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform rating and announces Price Target of $8.